Results 201 to 210 of about 20,467 (239)

Serous macular detachment in diabetic cystoid macular oedema [PDF]

open access: yesActa Ophthalmologica, 2005
Abstract.Purpose:  To define serous macular detachment in patients with diabetic cystoid macular oedema (CME). Methods:  This study involved 78 eyes of 58 patients with diabetic CME. The patients underwent complete ophthalmic examination, fluorescein angiography and optical coherence tomography (OCT).
Murat Karaçorlu
exaly   +3 more sources

Diabetic macular oedema

The Lancet Diabetes & Endocrinology, 2017
Diabetic macular oedema, characterised by exudative fluid accumulation in the macula, is the most common form of sight-threatening retinopathy in people with diabetes. It affects one in 15 people with diabetes resulting in more than 20 million cases worldwide.
Gavin S, Tan   +4 more
openaire   +2 more sources

Therapeutic Options in Refractory Diabetic Macular Oedema

Drugs, 2017
Diabetic macular oedema (DMO) results from alterations of several biochemical pathways in diabetic eyes. Centre-involving DMO is an important cause of visual loss in diabetes. Anti-vascular endothelial growth factor agents are now the mainstay of centre-involving DMO treatment.
Sanket U, Shah, Raj K, Maturi
openaire   +2 more sources

FUNDUS AUTOFLUORSECNCE IN DIABETIC MACULAR OEDEMA

INDIAN JOURNAL OF APPLIED RESEARCH, 2022
ntroduction: Diabetic macular oedema accounts for more than half the cases of vision loss in diabetics. With a shifting trend on early diagnosis and treatment of DME, fundus autouorescence may prove to be valuable. Traditional methods of 90d slit lamp examination and OCT may not detect early DME.
Uttara Pandit   +2 more
openaire   +1 more source

The effect of intravitreal triamcinolone on diabetic macular oedema

Graefe's Archive for Clinical and Experimental Ophthalmology, 2004
Diabetic macular oedema is a frequent cause of visual loss in patients with diabetic retinopathy. The purpose of this study was to assess the efficacy of intravitreal triamcinolone acetonide in reducing diabetic macular oedema and improving visual acuity.In this prospective study 12 eyes of 12 patients with diabetic macular oedema unresponsive to prior
Katharina, Krepler   +3 more
openaire   +2 more sources

The Use of Intravitreal Etanercept in Diabetic Macular Oedema

Seminars in Ophthalmology, 2007
The aim of this pilot study was to investigate the effect of intravitreal administration of etanercept in refractory diabetic macular edema. Seven patients diagnosed with diabetic macular edema, refractory to previous treatment, were enrolled. They all received 2 consecutive intravitreal injections of 2.5 mg (0, 1 ml) of Etanercept (Enbrel), with a two-
Miltiadis K, Tsilimbaris   +5 more
openaire   +2 more sources

Macular oedema and retinal neovascularisation in juvenile diabetics

International Ophthalmology, 1992
Thirteen young diabetic patients with peripheral capillary non perfusion who presented with symptoms of mild maculopathy were reviewed retrospectively. In this group, peripheral retinal ischaemia was often overlooked and a rapidly progressive proliferative retinopathy developed. Fluorescein angiography of the peripheral retina showed capillary closure,
P J, Polkinghorne   +2 more
openaire   +2 more sources

[Pathogenesis of diabetic macular oedema].

Klinische Monatsblatter fur Augenheilkunde, 2004
Hyperglycaemia causes breakdown of the blood retina barrier leading to formation of macular oedema and consecutive visual loss. Three major mechanisms are involved in barrier breakdown: increased paracellular permeability of vascular endothelium due to disruption of cell junctions, loss of endothelial cell layer integrity due to cell destruction, and ...
Tim U, Krohne   +3 more
openaire   +1 more source

Home - About - Disclaimer - Privacy